Recently J&J’s Risperdal, a drug formerly approved to treat schizophrenia, was approved to treat irritability symptoms stemming from autism. A group has taken issue with the ruling, claiming that the risks (including the risk of tardive dyskinesia) outweigh the benefits.
Filed under: Autism, Drug industry | Leave a Comment »